Opioid growth factor (OGF) and low dose naltrexone (LDN) inhibit immunological responses associated with EAE

被引：0

作者：

Rahn, Kristen A. ^{[1
]}

Bonneau, Robert H. ^{[1
]}

Turel, Anthony P. ^{[1
]}

Thomas, Gary A. ^{[1
]}

McLaughlin, Patricia J. ^{[1
]}

Zagon, Ian S. ^{[1
]}

机构：

[1] Penn State Univ, Hershey, PA USA

来源：

MULTIPLE SCLEROSIS | 2008年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S234 / S234

页数：1

共 19 条

[1] The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice
Donahue, Renee N.
McLaughlin, Patricia J.
Zagon, Ian S.
GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 382 - 388
[2] Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis
Rahn, Kristen A.
McLaughlin, Patricia J.
Zagon, Ian S.
BRAIN RESEARCH, 2011, 1381 : 243 - 253
[3] Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: A review
McLaughlin, Patricia J.
Sassani, Joseph W.
Klocek, Matthew S.
Zagon, Ian S.
BRAIN RESEARCH BULLETIN, 2010, 81 (2-3) : 236 - 247
[4] Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model
Donahue, Renee N.
McLaughlin, Patricia J.
Zagon, Ian S.
EXPERIMENTAL BIOLOGY AND MEDICINE, 2011, 236 (09) : 1036 - 1050
[5] The opioid growth factor (OGF)-OGF Receptor axis uses the p16 pathway to inhibit head and neck cancer
Cheng, Fan
Zagon, Ian S.
Verderame, Michael F.
McLaughlin, Patricia J.
CANCER RESEARCH, 2007, 67 (21) : 10511 - 10518
[6] Opioid growth factor (OGF) prevents relapses in mice with relapsing-remitting EAE, a model for multiple sclerosis
Hammer, Leslie A.
Zagon, Ian S.
McLaughlin, Patricia J.
FASEB JOURNAL, 2013, 27
[7] The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone
Zagon, Ian S.
Rahn, Kristen A.
FASEB JOURNAL, 2011, 25
[8] Short term opioid receptor blockade inhibits cancer cell proliferation independent of immune function by upregulation of the OGF-OGFr axis: A tissue culture model of low dose naltrexone (LDN)
Donahue, Renee N.
McLaughlin, Patricia J.
Zagon, Ian S.
CANCER RESEARCH, 2010, 70
[9] Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts
Tanaka, Kenjiro
Kondo, Hisataka
Hamamura, Kazunori
Togari, Akifumi
LIFE SCIENCES, 2019, 224 : 232 - 240
[10] Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial
Badaras, Robertas
Jovaisa, Tomas
Lapinskiene, Indre
Ivaskevicius, Juozas
JOURNAL OF ADDICTION MEDICINE, 2020, 14 (03) : 253 - 260

← 1 2 →